Skip to content
June 29, 2022

Equity.Guru

Investment information for the new generation

PHRM.C

Revive Therapeutics (RVV.C) provided an update on their psilocybin development programs today. “Revive is building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders….
PharmaTher (PHRM.C) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also…
+326% wtf? PharmaTher (PHRM.C), the Vancouver-based psychedelics company is on an impressive run. In the last month, the stock has rocketed from $0.19 CAD up to $0.81 CAD, a…
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin today, according to a…
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a press release. PharmaTher is…
One of the unfortunate downsides of living in the 21st century is the fact that most of us will have to deal with cancer in our lifetimes. The numbers…